Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant

Robert B. Belshe, Sharon E. Frey, Irene Graham, Mark J. Mulligan, Srilatha Edupuganti, Lisa A. Jackson, Anna Wald, Gregory Poland, Robert Jacobson, Harry L. Keyserling, Paul Spearman, Heather Hill, Mark Wolff

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background. The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). Methods. The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 lg of antigen was evaluated in healthy adults 18-49 years of age. Results. Two doses of vaccine were required to induce antibody titers ≥1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. Conclusions. An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.

Original languageEnglish (US)
Pages (from-to)666-673
Number of pages8
JournalJournal of Infectious Diseases
Volume203
Issue number5
DOIs
StatePublished - Mar 1 2011

Fingerprint

Subunit Vaccines
Human Influenza
Appointments and Schedules
Vaccines
Safety
Vaccination
Viruses
Injections
Antigens
Indonesia
Antibodies
Vietnam
Influenza Vaccines
Hemagglutinins
Antibody Formation
Registries
Proteins
Clinical Trials

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Belshe, R. B., Frey, S. E., Graham, I., Mulligan, M. J., Edupuganti, S., Jackson, L. A., ... Wolff, M. (2011). Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant. Journal of Infectious Diseases, 203(5), 666-673. https://doi.org/10.1093/infdis/jiq093

Safety and immunogenicity of influenza A H5 subunit vaccines : Effect of vaccine schedule and antigenic variant. / Belshe, Robert B.; Frey, Sharon E.; Graham, Irene; Mulligan, Mark J.; Edupuganti, Srilatha; Jackson, Lisa A.; Wald, Anna; Poland, Gregory; Jacobson, Robert; Keyserling, Harry L.; Spearman, Paul; Hill, Heather; Wolff, Mark.

In: Journal of Infectious Diseases, Vol. 203, No. 5, 01.03.2011, p. 666-673.

Research output: Contribution to journalArticle

Belshe, RB, Frey, SE, Graham, I, Mulligan, MJ, Edupuganti, S, Jackson, LA, Wald, A, Poland, G, Jacobson, R, Keyserling, HL, Spearman, P, Hill, H & Wolff, M 2011, 'Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant', Journal of Infectious Diseases, vol. 203, no. 5, pp. 666-673. https://doi.org/10.1093/infdis/jiq093
Belshe, Robert B. ; Frey, Sharon E. ; Graham, Irene ; Mulligan, Mark J. ; Edupuganti, Srilatha ; Jackson, Lisa A. ; Wald, Anna ; Poland, Gregory ; Jacobson, Robert ; Keyserling, Harry L. ; Spearman, Paul ; Hill, Heather ; Wolff, Mark. / Safety and immunogenicity of influenza A H5 subunit vaccines : Effect of vaccine schedule and antigenic variant. In: Journal of Infectious Diseases. 2011 ; Vol. 203, No. 5. pp. 666-673.
@article{d90cbffe413648e384858232ea88b91f,
title = "Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant",
abstract = "Background. The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). Methods. The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 lg of antigen was evaluated in healthy adults 18-49 years of age. Results. Two doses of vaccine were required to induce antibody titers ≥1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. Conclusions. An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.",
author = "Belshe, {Robert B.} and Frey, {Sharon E.} and Irene Graham and Mulligan, {Mark J.} and Srilatha Edupuganti and Jackson, {Lisa A.} and Anna Wald and Gregory Poland and Robert Jacobson and Keyserling, {Harry L.} and Paul Spearman and Heather Hill and Mark Wolff",
year = "2011",
month = "3",
day = "1",
doi = "10.1093/infdis/jiq093",
language = "English (US)",
volume = "203",
pages = "666--673",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Safety and immunogenicity of influenza A H5 subunit vaccines

T2 - Effect of vaccine schedule and antigenic variant

AU - Belshe, Robert B.

AU - Frey, Sharon E.

AU - Graham, Irene

AU - Mulligan, Mark J.

AU - Edupuganti, Srilatha

AU - Jackson, Lisa A.

AU - Wald, Anna

AU - Poland, Gregory

AU - Jacobson, Robert

AU - Keyserling, Harry L.

AU - Spearman, Paul

AU - Hill, Heather

AU - Wolff, Mark

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background. The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). Methods. The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 lg of antigen was evaluated in healthy adults 18-49 years of age. Results. Two doses of vaccine were required to induce antibody titers ≥1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. Conclusions. An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.

AB - Background. The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus). Methods. The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 lg of antigen was evaluated in healthy adults 18-49 years of age. Results. Two doses of vaccine were required to induce antibody titers ≥1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month. Conclusions. An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053.

UR - http://www.scopus.com/inward/record.url?scp=79751471067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751471067&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiq093

DO - 10.1093/infdis/jiq093

M3 - Article

C2 - 21282194

AN - SCOPUS:79751471067

VL - 203

SP - 666

EP - 673

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -